These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 19338571)

  • 21. Cyproterone acetate in topical delivery system.
    Lascu Z; Plakogiannis FM
    J Cosmet Sci; 2002; 53(5):299-301. PubMed ID: 12391999
    [No Abstract]   [Full Text] [Related]  

  • 22. Cyproterone for treatment of hypersexuality in an elderly Huntington's disease patient.
    Tavares A; Volpe FM
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1994-5. PubMed ID: 18691628
    [No Abstract]   [Full Text] [Related]  

  • 23. Cyproterone acetate--indications restricted because of hepatotoxicity and possible carcinogenicity.
    Ceylon Med J; 1996 Jun; 41(2):80-1. PubMed ID: 8771956
    [No Abstract]   [Full Text] [Related]  

  • 24. Successful treatment of idiopathic priapism in a 13-year-old boy.
    Palmer B; Frimberger D
    J Pediatr Urol; 2009 Apr; 5(2):145-6. PubMed ID: 18977180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation therapy for node-positive prostate cancer: adjuvant does not mean salvage.
    Culine S
    J Clin Oncol; 2009 Jun; 27(17):2888; author reply 2888. PubMed ID: 19398568
    [No Abstract]   [Full Text] [Related]  

  • 26. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. Commentary.
    Koupparis A
    BJU Int; 2009 Jul; 104(1):124; author reply 124-5. PubMed ID: 19646128
    [No Abstract]   [Full Text] [Related]  

  • 27. Degarelix (firmagon) for prostate cancer.
    Med Lett Drugs Ther; 2009 Oct; 51(1323):82-3. PubMed ID: 19838145
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of recurrent priapism in sickle cell anemia with finasteride: a new approach.
    Rachid-Filho D; Cavalcanti AG; Favorito LA; Costa WS; Sampaio FJ
    Urology; 2009 Nov; 74(5):1054-7. PubMed ID: 19616292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer.
    Dale W
    J Clin Oncol; 2009 Jul; 27(21):3420-2. PubMed ID: 19506150
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral midodrine for prostaglandin e1 induced priapism in spinal cord injured patients.
    Soler JM; Previnaire JG; Mieusset R; Plante P
    J Urol; 2009 Sep; 182(3):1096-100. PubMed ID: 19616810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW
    Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract]   [Full Text] [Related]  

  • 32. StatBite: Cause of Death Among Prostate Cancer Patients by Gleason Score.
    J Natl Cancer Inst; 2009 May; 101(9):623. PubMed ID: 19401547
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
    Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
    Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
    Gannon PO; Poisson AO; Delvoye N; Lapointe R; Mes-Masson AM; Saad F
    J Immunol Methods; 2009 Aug; 348(1-2):9-17. PubMed ID: 19552894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hirsutism.
    Shah D; Patel S
    Gynecol Endocrinol; 2009 Apr; 25(4):205-7. PubMed ID: 19408170
    [No Abstract]   [Full Text] [Related]  

  • 36. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM; Ryan CJ
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Key targets of hormone treatment of prostate cancer. Part I: the androgen receptor and steroidogenic pathways.
    Pitts WR
    BJU Int; 2009 Nov; 104(9):1304. PubMed ID: 19824968
    [No Abstract]   [Full Text] [Related]  

  • 38. Treating female pattern hair loss. Noticeable hair loss can be deeply distressing. Here are some medical treatments that may help.
    Harv Womens Health Watch; 2009 Jun; 16(10):1-3. PubMed ID: 19673142
    [No Abstract]   [Full Text] [Related]  

  • 39. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Opinion in Urology. Prostate cancer. Current world literature.
    Curr Opin Urol; 2009 May; 19(3):327-34. PubMed ID: 19363350
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.